{"transactions":[{"id":733221,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:27.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":212,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-075300","document":"tm2618120-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075300/tm2618120-2_4seq1.xml","form_type":"4"}},{"id":733220,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:27.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26210,"source":{"system":"sec-edgar","filing":"0001104659-26-075300","document":"tm2618120-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075300/tm2618120-2_4seq1.xml","form_type":"4"}},{"id":765332,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":52500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":765331,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6845,"price":1.085,"value":7426.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":26175,"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":765330,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33020,"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":788205,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:00:39.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-057365","document":"tm2613630-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057365/tm2613630-2_4seq1.xml","form_type":"4"}},{"id":788204,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-07T23:00:39.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15520,"source":{"system":"sec-edgar","filing":"0001104659-26-057365","document":"tm2613630-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057365/tm2613630-2_4seq1.xml","form_type":"4"}},{"id":840967,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":247,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840966,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":97,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840965,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6520,"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840964,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6485,"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":949849,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:02:17.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":70282,"derivative":{"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-26-000838","document":"tm261931-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926000838/tm261931-4_4seq1.xml","form_type":"4"}},{"id":968809,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968808,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":130,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968807,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6452,"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968806,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6417,"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":1038985,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":317,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038984,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":163,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038983,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6384,"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038982,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6349,"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1073878,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:00:51.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-25-074370","document":"tm2522669-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925074370/tm2522669-2_4seq1.xml","form_type":"4"}},{"id":1083221,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-23T00:27:53.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the \"PSUs\"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025."}],"balance_after":6316,"source":{"system":"sec-edgar","filing":"0001104659-25-069702","document":"tm2521458-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925069702/tm2521458-3_4seq1.xml","form_type":"4"}},{"id":1109391,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:02:17.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":352,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-059981","document":"tm2518140-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925059981/tm2518140-3_4seq1.xml","form_type":"4"}},{"id":1109390,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:02:17.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":196,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-059981","document":"tm2518140-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925059981/tm2518140-3_4seq1.xml","form_type":"4"}},{"id":1109389,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-16T23:02:17.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1941,"source":{"system":"sec-edgar","filing":"0001104659-25-059981","document":"tm2518140-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925059981/tm2518140-3_4seq1.xml","form_type":"4"}},{"id":1109388,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-16T23:02:17.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1906,"source":{"system":"sec-edgar","filing":"0001104659-25-059981","document":"tm2518140-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925059981/tm2518140-3_4seq1.xml","form_type":"4"}},{"id":1185892,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-01T22:02:57.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1875,"derivative":{"exercise_price":1.2,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001104659-25-030680","document":"tm2511097-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925030680/tm2511097-2_4seq1.xml","form_type":"4"}},{"id":1203202,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:36:43.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":false,"shares":34,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":387,"derivative":{"underlying":"Common Stock","underlying_shares":34},"source":{"system":"sec-edgar","filing":"0001104659-25-024532","document":"tm259558-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925024532/tm259558-2_4seq1.xml","form_type":"4"}},{"id":1203201,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:36:43.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":false,"shares":31,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":229,"derivative":{"underlying":"Common Stock","underlying_shares":31},"source":{"system":"sec-edgar","filing":"0001104659-25-024532","document":"tm259558-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925024532/tm259558-2_4seq1.xml","form_type":"4"}},{"id":1203200,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-17T22:36:43.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":true,"shares":34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1873,"source":{"system":"sec-edgar","filing":"0001104659-25-024532","document":"tm259558-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925024532/tm259558-2_4seq1.xml","form_type":"4"}},{"id":1203199,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-17T22:36:43.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":true,"shares":31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1839,"source":{"system":"sec-edgar","filing":"0001104659-25-024532","document":"tm259558-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925024532/tm259558-2_4seq1.xml","form_type":"4"}},{"id":1304868,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-11T01:01:44.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 7, 2025, the Reporting Person was granted an option to purchase 270,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":270000,"derivative":{"exercise_price":0.4713,"expiration_date":"2035-01-07","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001104659-25-002691","document":"tm252892-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925002691/tm252892-5_4seq1.xml","form_type":"4"}},{"id":1327871,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5064,"derivative":{"underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1327870,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":2606,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1327869,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":225,"price":0.3512,"value":79.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023."}],"balance_after":28931,"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1327868,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":205,"price":0.3551,"value":72.7955,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023."}],"balance_after":29156,"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1327867,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":true,"shares":562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29361,"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1327866,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:03:35.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":28799,"source":{"system":"sec-edgar","filing":"0001104659-24-129457","document":"tm2431371-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924129457/tm2431371-1_4seq1.xml","form_type":"4"}},{"id":1391366,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:54:47.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":7175,"price":0.55,"value":3946.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5501. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":28278,"source":{"system":"sec-edgar","filing":"0001104659-24-106062","document":"tm2425607-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924106062/tm2425607-3_4seq1.xml","form_type":"4"}},{"id":1391365,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:54:47.000Z","date":"2024-09-17","kind":"grant","planned":true,"acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the \"PSUs\"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024."}],"balance_after":35453,"source":{"system":"sec-edgar","filing":"0001104659-24-106062","document":"tm2425607-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924106062/tm2425607-3_4seq1.xml","form_type":"4"}},{"id":1404526,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:23:09.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":false,"shares":563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5625,"derivative":{"underlying":"Common Stock","underlying_shares":563},"source":{"system":"sec-edgar","filing":"0001104659-24-100752","document":"tm2424255-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100752/tm2424255-7_4seq1.xml","form_type":"4"}},{"id":1404525,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:23:09.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3127,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-100752","document":"tm2424255-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100752/tm2424255-7_4seq1.xml","form_type":"4"}},{"id":1404524,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:23:09.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":355,"price":0.6893,"value":244.7015,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023."}],"balance_after":14203,"source":{"system":"sec-edgar","filing":"0001104659-24-100752","document":"tm2424255-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100752/tm2424255-7_4seq1.xml","form_type":"4"}},{"id":1404523,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:23:09.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":true,"shares":563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":14558,"source":{"system":"sec-edgar","filing":"0001104659-24-100752","document":"tm2424255-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100752/tm2424255-7_4seq1.xml","form_type":"4"}},{"id":1404522,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:23:09.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":13995,"source":{"system":"sec-edgar","filing":"0001104659-24-100752","document":"tm2424255-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924100752/tm2424255-7_4seq1.xml","form_type":"4"}},{"id":1474431,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:27:09.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6188,"derivative":{"underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001104659-24-073004","document":"tm2417544-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073004/tm2417544-7_4seq1.xml","form_type":"4"}},{"id":1474430,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:27:09.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3648,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-073004","document":"tm2417544-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073004/tm2417544-7_4seq1.xml","form_type":"4"}},{"id":1474429,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:27:09.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":372,"price":1.28,"value":476.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023."}],"balance_after":13474,"source":{"system":"sec-edgar","filing":"0001104659-24-073004","document":"tm2417544-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073004/tm2417544-7_4seq1.xml","form_type":"4"}},{"id":1474428,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:27:09.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":true,"shares":562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":13846,"source":{"system":"sec-edgar","filing":"0001104659-24-073004","document":"tm2417544-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073004/tm2417544-7_4seq1.xml","form_type":"4"}},{"id":1474427,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:27:09.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":13284,"source":{"system":"sec-edgar","filing":"0001104659-24-073004","document":"tm2417544-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924073004/tm2417544-7_4seq1.xml","form_type":"4"}},{"id":1545151,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:30:07.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001104659-24-044857","document":"tm2411220-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044857/tm2411220-1_4seq1.xml","form_type":"4"}},{"id":1545150,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:30:07.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4169,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-044857","document":"tm2411220-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044857/tm2411220-1_4seq1.xml","form_type":"4"}},{"id":1545149,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:30:07.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":1067,"price":2.635,"value":2811.545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $2.61 to $2.66. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $2.61 to $2.66. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote."}],"balance_after":12763,"source":{"system":"sec-edgar","filing":"0001104659-24-044857","document":"tm2411220-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044857/tm2411220-1_4seq1.xml","form_type":"4"}},{"id":1545148,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:30:07.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":13830,"source":{"system":"sec-edgar","filing":"0001104659-24-044857","document":"tm2411220-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044857/tm2411220-1_4seq1.xml","form_type":"4"}},{"id":1545147,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:30:07.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":11580,"source":{"system":"sec-edgar","filing":"0001104659-24-044857","document":"tm2411220-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924044857/tm2411220-1_4seq1.xml","form_type":"4"}},{"id":1706596,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-18T21:57:02.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4690,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-126926","document":"tm2333119-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923126926/tm2333119-5_4seq1.xml","form_type":"4"}},{"id":1706595,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:57:02.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":11059,"source":{"system":"sec-edgar","filing":"0001104659-23-126926","document":"tm2333119-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923126926/tm2333119-5_4seq1.xml","form_type":"4"}},{"id":1778614,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-18T20:49:54.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5211,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-101641","document":"tm2326350-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923101641/tm2326350-3_4seq1.xml","form_type":"4"}},{"id":1778613,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-09-18T20:49:54.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10538,"source":{"system":"sec-edgar","filing":"0001104659-23-101641","document":"tm2326350-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923101641/tm2326350-3_4seq1.xml","form_type":"4"}},{"id":1851251,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-16T22:44:32.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5732,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-072398","document":"tm2319006-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923072398/tm2319006-4_4seq1.xml","form_type":"4"}},{"id":1851250,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-06-16T22:44:32.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10017,"source":{"system":"sec-edgar","filing":"0001104659-23-072398","document":"tm2319006-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923072398/tm2319006-4_4seq1.xml","form_type":"4"}},{"id":1949537,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T22:01:20.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":32000,"derivative":{"exercise_price":19.6,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-23-033406","document":"tm239796-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033406/tm239796-5_4seq1.xml","form_type":"4"}},{"id":1949536,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:01:20.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-23-033406","document":"tm239796-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033406/tm239796-5_4seq1.xml","form_type":"4"}},{"id":1949535,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:01:20.000Z","date":"2023-03-14","kind":"exercise","acquired":false,"shares":2084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6253,"derivative":{"underlying":"Common Stock","underlying_shares":2084},"source":{"system":"sec-edgar","filing":"0001104659-23-033406","document":"tm239796-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033406/tm239796-5_4seq1.xml","form_type":"4"}},{"id":1949534,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-16T22:01:20.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":985,"price":19.6911,"value":19395.7335,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6901 to 19.70. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9496,"source":{"system":"sec-edgar","filing":"0001104659-23-033406","document":"tm239796-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033406/tm239796-5_4seq1.xml","form_type":"4"}},{"id":1949533,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-16T22:01:20.000Z","date":"2023-03-14","kind":"exercise","acquired":true,"shares":2084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10481,"source":{"system":"sec-edgar","filing":"0001104659-23-033406","document":"tm239796-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923033406/tm239796-5_4seq1.xml","form_type":"4"}},{"id":2047203,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-25T01:08:20.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":50000,"price":30,"value":1500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $30.00 to $30.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":8397,"source":{"system":"sec-edgar","filing":"0001104659-23-006298","document":"tm232491-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923006298/tm232491-3_4seq1.xml","form_type":"4"}},{"id":2330130,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-16T20:15:43.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":33350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":33350,"derivative":{"exercise_price":15.31,"expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":33350},"source":{"system":"sec-edgar","filing":"0001104659-22-034484","document":"tm229449-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922034484/tm229449-1_4seq1.xml","form_type":"4"}},{"id":2330129,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-16T20:15:43.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":8337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":8337,"derivative":{"underlying":"Common Stock","underlying_shares":8337},"source":{"system":"sec-edgar","filing":"0001104659-22-034484","document":"tm229449-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922034484/tm229449-1_4seq1.xml","form_type":"4"}},{"id":2769019,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T00:49:07.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 25, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":22000,"derivative":{"exercise_price":41.17,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-21-043485","document":"tm217124d13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921043485/tm217124d13_4seq1.xml","form_type":"4"}},{"id":2780739,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-17T21:00:36.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":630,"price":49.3,"value":31059.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.03 to $49.44. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":58397,"source":{"system":"sec-edgar","filing":"0001104659-21-037765","document":"tm217124-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921037765/tm217124-9_4seq1.xml","form_type":"4"}},{"id":2780738,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-17T21:00:36.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":14370,"price":48.47,"value":696513.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.96. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":59027,"source":{"system":"sec-edgar","filing":"0001104659-21-037765","document":"tm217124-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921037765/tm217124-9_4seq1.xml","form_type":"4"}},{"id":2848676,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":600,"price":61.2,"value":36720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.09 to $61.75. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":73397,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848675,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":1772,"price":60.43,"value":107081.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.11 to $60.92. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":73997,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848674,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":500,"price":59.46,"value":29730.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.02 to $59.62. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":75769,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848673,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2886,"price":58.54,"value":168946.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.02 to $58.98. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":76269,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848672,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":1137,"price":57.71,"value":65616.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.12 to $57.88. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":79155,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848671,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":6805,"price":56.49,"value":384414.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.96. The reporting person undertakes to provide the Company, any security holder of the Company, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":80292,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2848670,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-18T21:56:10.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":1300,"price":55.88,"value":72644.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.78 to $55.99. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any\nsecurity holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":87097,"source":{"system":"sec-edgar","filing":"0001104659-21-025271","document":"tm217124-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921025271/tm217124-1_4seq1.xml","form_type":"4"}},{"id":2893108,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested and became exercisable as to 37,209 underlying shares on March 31, 2018, and the remaining 75% of underlying shares have vested or will vest in substantially equal monthly installments over the 36 months between August 23, 2018 and August 22, 2021, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":54310,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":2893107,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":4107,"price":49.35,"value":202680.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.74. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":88397,"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":2893106,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":6521,"price":48.39,"value":315551.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.02 to $48.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":92504,"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":2893105,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":3472,"price":47.62,"value":165336.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.01 to $47.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":99025,"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":2893104,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":900,"price":46.94,"value":42246.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.875 to $46.97. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":102497,"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":2893103,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-27T21:25:53.000Z","date":"2021-01-25","kind":"exercise","acquired":true,"shares":15000,"price":0.41,"value":6150.0,"ownership":{"direct":true},"balance_after":103397,"source":{"system":"sec-edgar","filing":"0001104659-21-008192","document":"tm214345d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921008192/tm214345d1_4seq1.xml","form_type":"4"}},{"id":3131675,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-28T20:16:15.000Z","date":"2020-05-26","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of May 26, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":45000,"derivative":{"exercise_price":45.99,"expiration_date":"2030-05-25","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-20-067057","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465920067057/a4.xml","form_type":"4"}},{"id":3261811,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2020-02-19T22:22:04.000Z","date":"2020-02-14","kind":"exercise","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is vested and became exercisable with respect to 10,146 shares and, with respect to the remaining 59,164 shares, will vest equally over the next 19 months from February 22, 2020 through August 22, 2021."}],"balance_after":69310,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-20-022899","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465920022899/a4.xml","form_type":"4"}},{"id":3261810,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-02-19T22:22:04.000Z","date":"2020-02-14","kind":"exercise","acquired":true,"shares":80000,"price":0.41,"value":32800.0,"ownership":{"direct":true},"balance_after":88397,"source":{"system":"sec-edgar","filing":"0001104659-20-022899","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465920022899/a4.xml","form_type":"4"}},{"id":3438386,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-08-14T20:15:21.000Z","date":"2019-08-13","kind":"purchase","acquired":true,"shares":6547,"price":8.67,"value":56762.49,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.50 to $8.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote."}],"balance_after":8397,"source":{"system":"sec-edgar","filing":"0001104659-19-045930","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465919045930/a4.xml","form_type":"4"}},{"id":3740657,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-12-06T11:04:01.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":450,"price":5.1973,"value":2338.785,"ownership":{"direct":true},"balance_after":1850,"source":{"system":"sec-edgar","filing":"0001104659-18-071465","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918071465/a4.xml","form_type":"4"}},{"id":3740656,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-12-06T11:04:01.000Z","date":"2018-12-03","kind":"purchase","acquired":true,"shares":450,"price":5.2299,"value":2353.455,"ownership":{"direct":true},"balance_after":1400,"source":{"system":"sec-edgar","filing":"0001104659-18-071465","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918071465/a4.xml","form_type":"4"}},{"id":3747173,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-11-30T22:35:08.000Z","date":"2018-11-30","kind":"purchase","acquired":true,"shares":450,"price":5.199,"value":2339.55,"ownership":{"direct":true},"balance_after":950,"source":{"system":"sec-edgar","filing":"0001104659-18-070875","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918070875/a4.xml","form_type":"4"}},{"id":3747171,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-11-30T19:31:37.000Z","date":"2018-11-29","kind":"purchase","acquired":true,"shares":500,"price":5.0223,"value":2511.15,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001104659-18-070795","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918070795/a4.xml","form_type":"4"}},{"id":3997508,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2018-03-13T21:11:39.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":36498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest as follows: 9,125 shares shall vest on March 12, 2019 and the remaining 27,374 shares shall vest monthly over 36 months from March 12, 2019 through March 12, 2022."}],"balance_after":185808,"derivative":{"exercise_price":11,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":36498},"source":{"system":"sec-edgar","filing":"0001104659-18-017147","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918017147/a4.xml","form_type":"4"}}]}